logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
G

Gwénaëlle Gravis

institut national de la sante et de la recherche medicale (inserm)

65H-index
736Paper Count
2.4WCitation Count
Published Papers 214
Publication Date
logo
Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
errEuropean Journal of Cancer
IF7.1
err2026-05-27
err0
errOAAI
errMarit Ahrens; John Haanen; Laurence Albiges; Marine Gross Goupil; Ekaterini Boleti; Gwenaelle Gravis; Aude Fléchon; Marc Oliver Grimm; Jens Bedke; Philippe Barthélémy; Daniel Castellano; Begona Mellado; Philipp Ivanyi; Sylvie Rottey; Anne Flörcken; Cristina Suárez; Jose P. Maroto; Viktor Grünwald; Sjoukje Oosting; Jindrich Kopecky
errShare
errSave
Chemotherapy-induced anemia as a prognostic factor for overall survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy and cystectomy
errWorld Journal of Urology
IF2.9
err2026-05-14
err0
PREAI
errElsa Lafitte; Patrick Sfumato; Jochen Walz; Emilien Billon; Nicolas Branger; Cécile Vicier; Stanislas Rybikowski; Mathilde Guérin; Thomas Maubon; Mathilde Beaufils; Lorène Seguin; Naji Salem; Serge Brunelle; Géraldine Pignot; Gwenaelle Gravis
errShare
errSave
Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study
errBritish Journal of Cancer
IF6.8
err2026-02-06
err0
PREAI
errBenoit Blanchet; Alicja Puszkiel; Anne Jouinot; Mostefa Bennamoun; Denis Maillet; Delphine Borchiellini; Brigitte Laguerre; Diane Pannier; Marine Gross-Goupil; Christine Chevreau; Philippe Barthélémy; Christophe Tournigand; Elodie Coquan; Gwenaelle Gravis; Eve Lepicard; Wolf Herman Fridman; Catherine Sautes-Fridman; Stéphane Oudard; Cheng-Ming Sun; Yann-Alexandre Vano
errShare
errSave
Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum
errJournal of Cancer Policy
IF2
err2026-01-01
err0
errOAAI
errLacombe, Denis; Borges, Fabio Cardoso; Amariutei, Ana E.; Booth, Christopher M.; Brusselle, Guy; Casolino, Raffaella; Demolis, Pierre; Giuliani, Rosa; Goldstein, Daniel A.; Gravis, Gwenaelle; Kaiser, Martin; Korakis, Iphigenie; Radulovic, Momir; Sullivan, Richard; Tombal, Bertrand; Wieseler, Beate; Zaiac, Michael; Voltz-Girolt, Caroline; Pignatti, Francesco
errShare
errSave
Pathophysiological rationale and management of anxio-depressive syndrome among cancer patients
errBulletin du Cancer
IF0.8
err2026-01-01
err0
PREAI
errDemigne, Jean-Baptiste; Sylvestre, Vincent; Bruyat, Damien; Fazzolari, Cecilia; Proux, Aurelien; Gravis, Gwenaelle; Geraud, Arthur
errShare
errSave
Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
errAnnals of Oncology
IF65.4
err2025-12-18
err0
PREAI
errJ. Walz; G. Attard; A. Bjartell; P. Blanchard; E. Castro; E. Compérat; L. Emmett; S. Fanti; V. Fonteyne; S. Foulon; S. Gillessen; G. Gravis; N.D. James; D.E. Oprea-Lager; P. Ost; A. Padhani; C. Parker; R.M. Renard-Penna; M.A. Rubin; F. Saad
errShare
errSave
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study
errEuropean Urology
IF25.2
err2025-11-11
err0
PREAI
errRonan Flippot; Yann-Alexandre Vano; Cécile Dalban; Benoit Beuselinck; Aude Fléchon; Maxime Meylan; Damien Pouessel; Antoine Bougoüin; Catherine Sautes-Fridman; Gwenaelle Gravis; Nathalie Chaput; Stéphane Oudard; Aude Desnoyer; Brigitte Laguerre; Salem Chouaib; Philippe Barthelemy; Delphine Borchiellini; Lucia Carril-Ajuria; Marine Gross-Goupil; Wolf-Herman Fridman; Lionnel Geoffrois; Frederic Rolland; Antoine Thiery-Vuillemin; Florence Joly; Sylvain Ladoire; Florence Tantot; Sylvie Chabaud; Bernard Escudier; Nathalie Rioux-Leclercq; Laurence Albiges
errShare
errSave
Can bladder MRI avoid systematic second TURBT for patients with high-risk NMIBC?
errWorld Journal of Urology
IF2.9
err2025-10-15
err0
PREAI
errLouis Gobinet; Clément Klein; Serge Brunelle; Mathias Illy; Gwenaelle Gravis; Jochen Walz; Nicolas Branger; Geraldine Pignot
errShare
errSave
BTN2A1 acquisition through trogocytosis enhances Vγ9Vδ2 T cell cytotoxicity against autologous and cancer cells
errCell Reports
IF6.9
err2025-10-07
err0
errOAAI
errEmilien Billon; Caroline Imbert; Damien Bruyat; Pierre Grassi; Lucie Robert; Téo Fernez; Philippe Livrati; Amira Ben Amara; Marie-Sarah Rouvière; Manon Richaud; Nicolas Boucherit; Jacques A. Nunès; Renaud Sabatier; Éric Lambaudie; Anne-Sophie Chrétien; Gwenaëlle Gravis; Laurent Gorvel; Daniel Olive
errShare
errSave
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor–based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma
errEuropean Urology
IF25.2
err2025-09-30
err0
PREAI
errLaurence Albiges; Thomas Powles; Anand Sharma; Balaji Venugopal; Jens Bedke; Angelika Borkowetz; Gwenaelle Gravis; Berna C. Özdemir; Marco Julius Schnabel; Pascale Dutailly; Bryan Qvick; Valerie Perrot; Viktor Grünwald
errShare
errSave
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial
errEuropean Journal of Cancer
IF7.1
err2025-09-27
err0
PREAI
errAdrien Rousseau; Maryam Karimi; Stefan Michiels; Guilhem Roubaud; Xavier Maldonado; Stephane Supiot; Ray McDermott; Aude Flechon; Bertrand Tombal; Philippe Ronchin; Dominik Berthold; Jean-François Berdah; Gabriel Kacso; Gwenaelle Gravis; Fabio Calabro; Sophie Tartas; Xavier Muracciole; Helene Ribault; Karim Fizazi; Stéphanie Foulon
errShare
errSave
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
errAnnals of Oncology
IF65.4
err2025-04-01
err0
errOAAI
errL. Bergmann; L. Albiges; M. Ahrens; M. Gross-Goupil; E. Boleti; G. Gravis; A. Fléchon; M.-O. Grimm; J. Bedke; P. Barthélémy; D. Castellano; B. Mellado; P. Ivanyi; S. Rottey; A. Flörcken; C. Suarez; P. Maroto; V. Grünwald; S.F. Oosting; J. Kopecky; S. Zschäbitz; M. Boegemann; T. Buchler; G. Niegisch; P.J. Goebell; T. Waddell; F. Joly; F. Priou; M. Retz; S. Siemer; U. Zimmermann; D. Deckbar; I. Burkholder; A. Hartmann; J.B. Haanen
errShare
errSave
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial
errEUROPEAN JOURNAL OF CANCER
IF7.1
err2025-03-01
err1
PREAI
errRoubaud, Guilhem; Kostine, Marie; Mcdermott, Raymond S.; Bernard-Tessier, Alice; Maldonado, Xavier; Silva, Marlon; Flechon, Aude; Berthold, Dominik R.; Ronchin, Philippe; Tombal, Bertrand F.; Mourey, Loic; Gravis, Gwenaelle; Escande, Anne; Abadie-Lacourtoisie, Sophie; Maurina, Tristan; Climent, Miguel A.; Ribault, Helene; Bossi, Alberto; Foulon, Stephanie; Fizazi, Karim
errShare
errSave
Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) plus /- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errVano, Y-A.; Hernandez, I.; Bennamoun, M.; Verkarre, V.; Chevreau, C. M.; Goupil, M. Gross; Tournigand, C.; Borchiellini, D.; Laguerre, B.; Maillet, D.; Barthelemy, P.; Gravis, G.; Coquan, E.; Pannier, D.; Houede, N.; Kotti, S.; Fridman, W-H.; Sautes-Fridman, C.; Sun, C-M.; Oudard, S.
errShare
errSave
Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errBlanchet, B.; Puszkiel, A. A.; Jouinot, A.; Bennamoun, M.; Maillet, D.; Borchiellini, D.; Laguerre, B.; Pannier, D.; Goupil, M. Gross; Chevreau, C. M.; Barthelemy, P.; Tournigand, C.; Coquan, E.; Gravis, G.; Kotti, S.; Fridman, W-H.; Sautes-Fridman, C.; Oudard, S.; Sun, C-M.; Vano, Y-A.
errShare
errSave
Long survivors after androgen deprivation therapy (ADT) with or without docetaxel for metastatic castration-sensitive prostate cancer (mCSPC): Long-term follow-up of GETUG-15
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errBlanchet-Deverly, S.; Fizazi, K.; Oudard, S.; Gravis, G.; Boughalem, E.; Borchiellini, D.; Foulon, S.; Pradat, F. Peyre; Beuzeboc, P.; Mourey, L.; Laguerre, B.; Jacobs, M.; Tosi, D.; Priou, F.; Sfumato, P.; Massard, V.
errShare
errSave
Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: Results of the SUNNIFORECAST trial
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err8
PREAI
errBergmann, L.; Ahrens, M.; Albiges, L.; Goupil, M. Gross; Boleti, E.; Gravis, G.; Flechon, A.; Grimm, M-O. J.; Rausch, S.; Barthelemy, P.; Gauna, D. E. Castellano; Gonzalez, B. Mellado; Ivanyi, P.; Floercken, A.; Rodriguez, C. Suarez; Rey, J. P. Maroto; Gruenwald, V.; Burkholder, I.; Hartmann, A.; Haanen, J. B. A. G.
errShare
errSave
Efficacy of talazoparib and avelumab as a maintenance treatment in patients with advanced/metastatic urothelial carcinoma (mUC) whose disease did not progress after a first-line platinum-based chemotherapy (PBCT): The GETUG-TALASUR trial
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errCoquan, E.; Boughalem, E.; Pouessel, D.; Lequesne, J.; Calcagno, F.; Grellard, J-M.; Christy, F.; Mahammedi, H.; Ladoire, S.; Borchiellini, D.; Leman, R.; Bazille, C.; Fontugne, J.; Crouzet, L.; Flechon, A.; Serrate, C.; Gravis, G.; Clarisse, B.; Vuillemin, A. Thiery; Lobbedez, F. Joly
errShare
errSave
Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errFizazi, K.; Roubaud, G.; Bernard-Tessier, A.; Gravis, G.; Flechon, A.; Ratta, R.; Barthelemy, P.; Jones, R. J.; Parikh, O. A.; Hussain, A.; van der Voet, J. C. M.; Cook, N.; Tanner, M. M. E.; Jones, R. H.; Garratt, C.; Ikonen, T.; Pohjanjousi, P.; Poehlein, C. H.; Antonarakis, E. S.
errShare
errSave
Hyperprogressive disease during immune checkpoint inhibitor: A cloudy phenomenon with real consequences
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errBruyat, D.; Girard, N.; Penel, N.; Heudel, P-E.; Goncalves, A.; Flandin, A-C. Madroszyk; Gravis, G.; Chanez, B.; Collineau, B.; Chretien, A-S.; Beaufils, M.; Billon, E.; Rochigneux, P.
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
G
Georgina V. Long
H-index: 169 · Papers: 1.8K
L
Laurence Zitvogel
H-index: 165 · Papers: 1.2K
J
Johann S. de Bono
H-index: 160 · Papers: 2.5K
T
Toni K. Choueiri
H-index: 149 · Papers: 2.4K
R
Robert J. Motzer
H-index: 148 · Papers: 1.6K
View more